Habib Haybar, Babak Ramezani, Ahmad Reza Assareh, Ali Kardooni, Shirin Azizidoost
{"title":"钙粘蛋白与 STEMI 患者 LVEF 水平降低和心律失常的发生有关。","authors":"Habib Haybar, Babak Ramezani, Ahmad Reza Assareh, Ali Kardooni, Shirin Azizidoost","doi":"10.4103/abr.abr_438_23","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Calprotectin is recognized as a promising prognostic as well as a diagnostic marker of cardiac disorders. In the present study, we aimed to survey the efficiency of serum calprotectin levels in anticipating the severity of coronary artery disease (CAD) along with in-hospital major adverse cardiovascular events (MACE) in patients with ST-segment elevation (STEMI) underlying primary percutaneous coronary intervention (PCI).</p><p><strong>Materials and methods: </strong>A total of 97 patients with STEMI participated and were evaluated for in-hospital MACE for possible correlation with serum calprotectin.</p><p><strong>Results: </strong>Increased levels of serum calprotectin showed positive and negative correlation with severity of coronary arteries and left ventricular ejection fraction (LVEF) of STEMI patients, respectively. Regarding in-hospital MACE, only arrhythmia showed a significant relationship in patients with high calprotectin levels.</p><p><strong>Conclusion: </strong>High calprotectin levels may be a prognostic marker for occluded artery and LVEF in STEMI patients.</p>","PeriodicalId":94292,"journal":{"name":"Advanced biomedical research","volume":"13 ","pages":"90"},"PeriodicalIF":0.7000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542697/pdf/","citationCount":"0","resultStr":"{\"title\":\"Calprotectin Correlates with Reduced Level of LVEF and Occurrence of Cardiac Arrhythmia in STEMI Patients.\",\"authors\":\"Habib Haybar, Babak Ramezani, Ahmad Reza Assareh, Ali Kardooni, Shirin Azizidoost\",\"doi\":\"10.4103/abr.abr_438_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Calprotectin is recognized as a promising prognostic as well as a diagnostic marker of cardiac disorders. In the present study, we aimed to survey the efficiency of serum calprotectin levels in anticipating the severity of coronary artery disease (CAD) along with in-hospital major adverse cardiovascular events (MACE) in patients with ST-segment elevation (STEMI) underlying primary percutaneous coronary intervention (PCI).</p><p><strong>Materials and methods: </strong>A total of 97 patients with STEMI participated and were evaluated for in-hospital MACE for possible correlation with serum calprotectin.</p><p><strong>Results: </strong>Increased levels of serum calprotectin showed positive and negative correlation with severity of coronary arteries and left ventricular ejection fraction (LVEF) of STEMI patients, respectively. Regarding in-hospital MACE, only arrhythmia showed a significant relationship in patients with high calprotectin levels.</p><p><strong>Conclusion: </strong>High calprotectin levels may be a prognostic marker for occluded artery and LVEF in STEMI patients.</p>\",\"PeriodicalId\":94292,\"journal\":{\"name\":\"Advanced biomedical research\",\"volume\":\"13 \",\"pages\":\"90\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542697/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced biomedical research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/abr.abr_438_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/abr.abr_438_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Calprotectin Correlates with Reduced Level of LVEF and Occurrence of Cardiac Arrhythmia in STEMI Patients.
Background: Calprotectin is recognized as a promising prognostic as well as a diagnostic marker of cardiac disorders. In the present study, we aimed to survey the efficiency of serum calprotectin levels in anticipating the severity of coronary artery disease (CAD) along with in-hospital major adverse cardiovascular events (MACE) in patients with ST-segment elevation (STEMI) underlying primary percutaneous coronary intervention (PCI).
Materials and methods: A total of 97 patients with STEMI participated and were evaluated for in-hospital MACE for possible correlation with serum calprotectin.
Results: Increased levels of serum calprotectin showed positive and negative correlation with severity of coronary arteries and left ventricular ejection fraction (LVEF) of STEMI patients, respectively. Regarding in-hospital MACE, only arrhythmia showed a significant relationship in patients with high calprotectin levels.
Conclusion: High calprotectin levels may be a prognostic marker for occluded artery and LVEF in STEMI patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
